PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer

References

• UK CR Head and Neck Cancer Statistics. 2017; Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Zero.
   Google Scholar
• Byeon HK, Ku M, Yang J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp Mol Med. 2019;51(1):1–14.
   PubMedGoogle Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505–516.
   PubMed Web of Science ®Google Scholar
• Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res. 2009;315(4):572–582.
   PubMed Web of Science ®Google Scholar
• Olayioye MA., R.M. Neve, H.A. Lane, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000;19(13):3159–3167..
   PubMed Web of Science ®Google Scholar
• Rogers SJ, Harrington KJ, Rhys-Evans P, et al. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev. 2005;24(1):47–69..
   PubMed Web of Science ®Google Scholar
• Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–184.
   PubMed Web of Science ®Google Scholar
• Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003;284(1):122–130.
   PubMed Web of Science ®Google Scholar
• Wei Q, Sheng L, Shui Y, et al. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol. 2008;15(4):1193–1201..
   PubMed Web of Science ®Google Scholar
• Erjala, K., M. Sundvall, T.T. Junttila, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006;12(13):4103–4111..
   PubMed Web of Science ®Google Scholar
• Sacco AG, Worden FP. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther. 2016;9:1927–1943.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27(28):3944–3956..
   PubMed Web of Science ®Google Scholar
• Ferris RL, Licitra L, Fayette J, et al. Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in checkmate 141 by prior cetuximab use. Clin Cancer Res. 2019;25(17):5221–5230..
   PubMed Web of Science ®Google Scholar
• Kosti P, Maher J, Arnold JN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 2018;9:1104.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol. 2002;20(1):70–75..
   PubMed Web of Science ®Google Scholar
• Davies, D.M., J. Foster, S.J.C. Van Der Stegen, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Molecular medicine (Cambridge. Mass.). 2012;18(1):565–576.
   Google Scholar
• Wilkie S, Burbridge SE, Chiapero-Stanke L, et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem. 2010;285(33):25538–25544.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851..
   PubMed Web of Science ®Google Scholar
• van der Stegen SJC, Davies DM, Wilkie S, et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J Immunol. 2013;191(9):4589–4598..
   PubMed Web of Science ®Google Scholar
• Parente-Pereira AC, Burnet J, Ellison D, et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J Clin Immunol. 2011;31(4):710–718..
   PubMed Web of Science ®Google Scholar
• van Schalkwyk, M.C., S.E. Papa, J.P. Jeannon, et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev. 2013;24(3):134–142.
   PubMed Web of Science ®Google Scholar
• Parente-Pereira, A.C., L.M. Whilding, N. Brewig, et al. Synergistic chemoimmunotherapy of epithelial ovarian cancer using erBB-retargeted T cells combined with carboplatin. J Immunol. 2013;191(5):2437–2445.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928..
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28..
   PubMed Web of Science ®Google Scholar
• Biau J, Bourhis J. Combining immunotherapy and radiotherapy in head and neck squamous cell cancers: which perspectives? Curr Opin Oncol. 2020;32(3):196–202.
   PubMed Web of Science ®Google Scholar
• Klampatsa, A., D.Y. Achkova, D.M. Davies, et al. Intracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett. 2017;393:52–59.
   PubMed Web of Science ®Google Scholar